Corporate News – Cerus Corporation
Cerus (ticker CERS) finished Monday, 26 January 2026, trading 0.87 % higher during a 24‑hour period that ended at 11:04 AM Central Europe. At the close, one share of Cerus was priced at approximately USD 2.33 on major exchanges.
Market Metrics (as of 26 January 2026)
| Item | Value |
|---|---|
| Current supply of shares | 201.5 million |
| Market capitalization | USD 469.6 million |
| Volume traded in last 24 hrs | USD 4.5 million |
| 24‑hour price change | +0.87 % |
| 30‑day moving average | USD 2.33 |
| 200‑day simple moving average | USD 2.45 |
| 52‑week high | USD 3.47 (7 June 2026) |
| 52‑week low | USD 1.38 (11 June 2025) |
| Performance since last month‑end | -10.73 % |
Comparative Performance of Peer Stocks (last 24 hours)
| Company | Ticker | 24‑hr change | Current price (USD) | Market cap (USD million) | P/E ratio |
|---|---|---|---|---|---|
| Park Aerospace | PKE | +0.47 % | 25.70 | 559.0 | 35.84 |
| Myriad Genetics | MYGN | +1.04 % | 5.82 | 556.7 | – |
| Fulgent Genetics | FLGT | +0.55 % | 20.10 | 553.1 | – |
| Olema | OLMA | -8.69 % | 6.41 | 560.9 | – |
| Prokidney | PROK | -1.40 % | 1.41 | 562.8 | – |
Company Overview
Cerus Corporation is headquartered in Concord, United States. The company operates in the health‑care equipment and supplies sector, focusing on the development of systems that improve the safety of blood transfusions. Its products inactivate pathogens—including viruses, bacteria, and white blood cells—in blood components, thereby reducing the risk of adverse transfusion reactions. The company’s technology platform prevents viral, bacterial, and cellular replication and is designed to provide a high level of safety for blood transfusion recipients.
Cerus is listed on the Nasdaq. Further information about the company’s products, initiatives, and corporate updates can be found on its website at www.cerus.com .
